“GervanoRA’s Clinical trials report “Mild Cognitive Impairment: Comprehensive Global Clinical Trials Analytics H2 2018” provides an in-depth analysis of the overall clinical trials for Mild Cognitive Impairment. The report caters information related to the global clinical trials with respect to their Phase, Trial Status, Intervention, Trial type and Endpoint status. Our report exclusively focuses on providing insights and competitive opportunities based on Biomarker or target receptor, Drug Class and Mechanism of Action to aid in understanding the upcoming newer research trends in the field of Mild Cognitive Impairment drug discovery. The report offers coverage of Mild Cognitive Impairment clinical trials by region and average enrollment by country. Country based analytics are provided according to the Top 5 Clinical trial sites globally and the emerging countries supporting with a platform to conduct clinical trials effectively. Analytics are also provided for the subjects enrolled over a period of time, Mild Cognitive Impairment clinical trials by sponsor type and the top companies involved in the R&D of Mild Cognitive Impairment drug development. In addition, the report gives a brief overview on the major drugs undergoing trials and the recent advancements observed in the Mild Cognitive Impairment clinical trials.